Corporate Satellite Symposium Highlights Clinical Genomics, Precision Oncology, and Spatial Multi-omics
As part of ESHG 2026, MGI hosted a Corporate Satellite Symposium. Advances in diagnostics: from clinical implementation to biomarker discoverybrings together leading experts from across Europe to showcase how advanced genomic technologies are impacting real-world clinical and research practices. The symposium focused on applications across clinical tumor diagnostics, pharmacogenomics, and spatial multi-omics.
Dr. Raquel T. Lima from IPATIMUP (Portugal) presented the clinical value of RNA sequencing to detect actionable gene fusions in solid tumors, improve diagnostic yield, and support accurate oncology decision-making. Professor Andreas Braun from Schleswig-Holstein University Hospital, Germany, shared how spatial biology techniques map the tumor microenvironment in melanoma and reveal mechanisms related to tumor heterogeneity, cellular interactions, disease progression and treatment response. Dr. Andrea Conti from BMR Genomics (Italy) explored the potential of whole genome sequencing for pharmacogenetic marker assessment and highlighted how comprehensive genomic approaches can support the implementation of personalized medicine by improving the identification of clinically relevant variants.
These presentations demonstrated how genomic and multi-omics technologies are advancing clinical diagnostics, translational oncology research, and precision medicine, while highlighting the growing role of sequencing in providing actionable insights across healthcare and biomedical research.
A comprehensive solution for genomics and multi-omics research
Visitors to the MGI booth can explore the company’s comprehensive portfolio of sequencing and automation technologies that support applications across human genetics, oncology, reproductive health, population genomics, and multi-omics research.
To highlight robust market adoption, MGI will be showcasing its ultra-high throughput sequencing platform, T7+, at the conference. After being officially launched for the European and African regions at Analytica 2026 in Munich, the T7+ has gained significant momentum, with 27 units installed worldwide as of the end of 2025. From benchtop to ultra-high-throughput sequencing platforms and advanced test automation solutions, MGI continues to support laboratories seeking high-performance, scalable, and cost-effective genomics workflows.
“Our mission goes beyond providing innovative technology,” said Dr. Christian Zimmerman, MGI’s vice president of sales for Europe and Africa. “We are focused on building a complete ecosystem that enables our customers to seamlessly transition from research to clinical implementation. The partnerships and initiatives we are launching at ESHG 2026 demonstrate our commitment to making genomic technologies more accessible, integrated, and impactful.”
Driving the future of precision medicine in Europe
Europe remains a strategic region for MGI, with increasing adoption of genomic technologies across research institutions, healthcare systems and national population initiatives.
MGI is helping accelerate the transition to more accurate, data-driven medicine through continued investments in sequencing innovation, automation, clinical partnerships, and collaborative ecosystem development.
As genomics becomes increasingly integrated into daily clinical practice, MGI remains committed to providing the technology and partnerships needed to support the next generation of precision medicine.
